Monthly Part B Premiums and Annual Percentage Increases


In November 2021, CMS announced that the monthly Medicare Part B premium would increase from $ 148.50 in 2021 to $ 170.10 in 2022, an increase of 14.5% ($ 21.60). This is the largest increase in dollar terms since the start of the program, although premiums have increased faster in percentage terms on three other occasions in the last 20 years – 2016 (16.1%), 2010 (14.6%) and 2005 (17.4%).

CMS explained that the increase for 2022 was due in part to the potential costs associated with the new Alzheimer’s disease drug, Aduhelm (aducanumab), made by Biogen, which had an initial annual price of $ 56,000. The Part B premium increase was intended to allow a ‘high cost scenario’ of Aduhelm coverage based on assumptions about the use of months before the planned announcement of a national coverage determination (NCD ).

A Proposed DEM was announced on Tuesday, January 11, which will be followed by a 30-day comment period and a final decision to be announced by April 11, 2022. NCD proposes to cover Aduhelm and other anti-amyloid monoclonal antibodies Similar FDA-approved coverage under Development of Evidence (CED) in approved randomized controlled trials that meet specific coverage criteria. This is because these drugs will not be covered for people on Medicare, unless they are part of an eligible clinical trial.

On January 10, HHS Secretary Xavier Becerra asked CMS to reassess the amount of the Medicare B 2022 premium to take into account a 50% reduction in the price of Aduhelm announced by Biogen at the end of December 2021. very unusual.


Comments are closed.